Additionally, miR-186-5p, which is down-regulated in cisplatin-resistant glioblastoma cells, targets YY1, weakens the sphere formation of glioblastoma cells, and improves the efficacy of chemotherapeutic agents [149] (Figure 2 and Table 4). Here, YY1 is linked to glioblastoma.